This site is intended for Healthcare Professionals outside the US

Toxicities frequently compromise the ability to dose HU at therapeutic levels1

More than 1 out of every 8 PV patients receiving HU is intolerant to the drug based on ELN criteria2

Rate of HU intolerance2

Rate of Hydroxyurea (HU) Intolerance in Polycythemia Vera Patients – JAKAVI

Patients with HU intolerance or HU resistance have had limited therapeutic options

  • For 59% of patients with HU resistance/intolerance in a Phase III clinical trial, HU was nonetheless considered their best available treatment3*

Learn about the well-characterised safety profile of JAKAVI

Next: Clinical benefit in PV with JAKAVI

*Based on 112 patients with HU resistance/intolerance who were randomised to the best available therapy (BAT) arm of a Phase III clinical trial.3
ELN=European LeukemiaNET; HU=hydroxyurea.

References:

  1. Najean Y, Rain J-D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90(9):3370-3377.
  2. Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363-1369.
  3. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435.